Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 31, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA, GSK, Novartis, Pfizer, environment, opioids, pharma, pricing

The pharmaceutical industry is a big polluter than the automotive industry. This was our top story this week. The findings …
News
merckwindow_web

NICE recommends MSD’s Prevymis for CMV prevention following allogeneic haematopoietic stem cell transplant

May 31, 2019 Medical Communications, Sales and Marketing MSD, NICE, Prevymis, UK, cmv, cytomegalovirus, pharma

MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …
News
mercier

Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer

May 30, 2019 Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …
News
novo_flag

Novo Holdings invests £53.5 million into Oxford Biomedica

May 30, 2019 Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus

Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …
News
celgene_building

FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma

May 29, 2019 Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma

Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …
News
katy_baker

Living with Scimitar syndrome

May 28, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Scimitar syndrome, patient experience, pharma

Katy Baker has lived her entire life with the rare congenital heart defect Scimitar syndrome. She reflects on the system …
Feature

Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures

May 28, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure

Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …
News
novartis_side_building

FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer

May 28, 2019 Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma

Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

May 24, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …
News
190131111631-01-shingles-vaccine-gsk-super-tease

China approves GSK’s shingles vaccine Shingrix

May 24, 2019 Medical Communications, Sales and Marketing China, GSK, Shingrix, pharma, shingles

GSK’s shingles vaccine has secured approval in China, the company said, after the National Medical Products Administration (NMPA) authorised the …
News
spravato

Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression

May 23, 2019 Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression

Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …
News

Akcea’s Tegsedi secures NICE approval for Stage 1 or 2 polyneuropathy in hATTR

May 23, 2019 Sales and Marketing Akcea Therapeutics, NHS, NICE, Tegsedi, UK, pharma

Akcea Therapeutics’ Tegsedi (inotersen) has received recommendation from NICE, the company has revealed, meaning the therapy will now be made …
News
takeda_global_hq

Takeda scores Japanese Entyvio approval in Crohn’s disease

May 22, 2019 Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma

Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …
News
spravato

New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression

May 21, 2019 Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma

New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …
News
antibiotic-resistance-pill-running-from-bacteria-1500

The global rise in antibiotic resistance threatens infection prevention and cure

May 20, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance, antimicrobial resistance, feature, pharma

Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic …
Feature
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026